Drug/device combinations rising: could EMA cope?
This article was originally published in Clinica
Executive Summary
Figures from a recent survey of the EU regulatory landscape should help determine the European Medicines Agency’s capacity to take on the responsibility for premarket authorization of some high-risk and innovative medical devices, including drug/device combination products.